🇺🇸 FDA
Patent

US 11649459

Superoxide dismutase 1 (SOD1) iRNA compositions and methods of use thereof for treating or preventing superoxide dismutase 1-(SOD1-) associated neurodegenerative diseases

granted A61PA61P25/00

Quick answer

US patent 11649459 (Superoxide dismutase 1 (SOD1) iRNA compositions and methods of use thereof for treating or preventing superoxide dismutase 1-(SOD1-) associated neurodegenerative diseases) held by Alnylam Pharmaceuticals, Inc. expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61P, A61P25/00